Shilpa Medicare’s Unit III, Advanced Analytical Characterization Laboratory situated at Dabaspet, Bengaluru in Karnataka has cleared US Food & Drug Administration (USFDA) remote record review without any objectionable conditions or observations. The review was conducted during November 15 to 18, 2021.
The facility is designed with advanced analytical equipment to provide testing services such as /n-vitro Permeation testing, Nitrosamine testing, Elemental Impurity testing, Extractable & Leachable testing, Glass Delamination testing etc.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
